ICE Bioscience Application Notes

Our previous application notes examined biochemical binding and ternary-complex formation and structural models for the AR–BRD4 RIPTAC II-5 (HLD-0915). The next question is whether the compound can achieve measurable systemic and tumor exposure under oral dosing conditions.

This case follows II-5 through early ADME profiling, formulation selection, mouse pharmacokinetics, and tissue distribution. Together, these measurements inform the choice of dosing conditions and sampling windows for subsequent pharmacodynamic studies.

Completed assays characterized II-5 plasma protein binding, liver microsome stability, CYP inhibition, and responses in selected human cell types. These measurements provide context for the subsequent mouse exposure studies.

An intravenous reference dose and seven oral conditions were evaluated in mice. The oral formulations differed in vehicle, fed state, and dose. PO7 used NKG mice; the other formulation-screening conditions used female BALB/c mice.

At 5 mg/kg under fasted conditions, observed oral bioavailability ranged from 0.296% with PO2 to 15.5% with PO1. PO1 and PO3 also produced substantially higher C_max and AUC_last than PO2. These comparisons show how strongly the measured exposure depended on the dosing vehicle in this experiment.

A separate 5 mg/kg oral tissue-distribution study in female BALB/c mice measured II-5 in plasma and selected tissues. The reported AUC_last ratios were 0.000499 for brain, 0.148 for kidney, 0.130 for liver, and 0.0312 for bone marrow relative to plasma.

In male NOD SCID mice bearing VCaP tumors, tissue concentrations were measured at 6 and 24 hours after a 30 mg/kg oral dose. The tumor concentration was 319 ng/g at 6 hours and remained measurable at 77.0 ng/g at 24 hours. Over the same interval, plasma concentration fell from 1,380 to 13.9 ng/mL, and the tumor-to-plasma concentration ratio rose from 0.231 to 5.54. Thus, the rising ratio reflects a slower decline in measured tumor concentration than in plasma; absolute tumor concentration did not increase.

In this AR–BRD4 RIPTAC case, oral vehicle choice produced markedly different systemic exposure at the same dose, and II-5 remained measurable in VCaP tumor tissue 24 hours after dosing. These data provide a basis for selecting formulations and tumor sampling times for subsequent pharmacodynamic and efficacy experiments, extending the earlier biochemical and structural characterization into a translational study design.